HOME HELP FEEDBACK ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Tosi, P. Articles by Tura, S. PubMed PubMed Citation Articles by Tosi, P. Articles by Tura, S.

Consensus conference on the management of tumor lysis syndrome

¹ Hematology Unit, Istituto Seragnoli, Ospedale Sant’Orsola Malpighi, Bologna
² Laboratory of Clinical Epidemiology, IRCCS Policlinico San Matteo Foundation, Pavia
³ Health Economist, Milan
⁴ Hematology Unit, Policlinico di Bari, Bari
⁵ Hematology Unit, Ospedale Niguarda, Milan
⁶ Pediatric Oncology Hematology Unit "Lalla Seràgnoli", Ospedale Sant’Orsola Malpighi, Bologna
⁷ Oncology Unit, Ospedale Regionale, Treviso
⁸ Nephrology Unit, Ospedale Malpighi, Bologna, Italy

Correspondence: Sante Tura, Istituto di Ematologia e Oncologia Medica "Seràgnoli", Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna, Italy. E-mail:sante.tura{at}ailbologna.it

ABSTRACT

Tumor lysis sindrome is a potentially life threatening complication of massive cellular lysis in cancers. Identification of high-risk patients and early recognition of the syndrome is crucial in the institution of appropriate treatments. Drugs that act on the metabolic pathway of uric acid to allantoin, like allopurinol or rasburicase, are effective for prophylaxis and treatment of tumor lysis sindrome. Sound recommendations should regulate diagnosis and drug application in the clinical setting. The current article reports the recommendations on the management of tumor lysis sindrome that were issued during a Consensus Conference project, and which were endorsed by the Italian Society of Hematology (SIE), the Italian Association of Pediatric Oncologists (AIEOP) and the Italian Society of Medical Oncology (AIOM). Current concepts on the pathophysiology, clinical features, and therapy of tumor lysis sindrome were evaluated by a Panel of 8 experts. A consensus was then developed for statements regarding key questions on tumor lysis sindrome management selected according to the criterion of relevance by group discussion. Hydration and rasburicase should be administered to adult cancer patients who are candidates for tumor-specific therapy and who carry a high risk of tumor lysis sindrome. Cancer patients with a low-risk of tumor lysis sindrome should instead receive hydration along with oral allopurinol. Hydration and rasburicase should also be administered to patients with clinical tumor lysis sindrome and to adults and high-risk children who develop laboratory tumor lysis sindrome. In conclusion, the Panel recommended rasburicase for tumor lysis sindrome prophylaxis in selected patients based on the drug efficacy profile. Methodologically rigorous studies are needed to clarify its cost-effectiveness profile.

Key words: tumor lysis sindrome, rasburicase, lymphoma.